# Expert Consensus on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer

## TL;DR

This paper provides guidelines for the proper use and monitoring of lung cancer targeted drugs to improve patient outcomes.

## Contribution

It offers a consensus on rational drug use and monitoring for 43 small molecule targeted drugs in lung cancer.

## Key findings

- The consensus covers drug selection, dosage adjustment, and monitoring of efficacy and side effects.
- It aims to enhance drug safety and effectiveness to improve survival and quality of life for lung cancer patients.

## Abstract

肺癌小分子靶向药物的临床应用显著改善了肺癌患者的生存期，但此类药物种类多、新药研发上市快、不良反应复杂且多为居家用药，增加了其不合理使用风险，同时疗效、安全性方面也容易出现监测不足的情况，最终影响治疗结局。本共识针对国内外上市的43种肺癌小分子靶向药物（或药物组合），为临床提供合理用药和疗效/不良反应监测的规范化建议，内容包括药物选择、剂量调整、疗效监测、不良反应监测、提高患者依从性等内容。本共识旨在提高肺癌小分子靶向药物合理用药水平和疗效/安全性监测质量，保障药物有效性与安全性，延长肺癌患者生存期，提升肺癌患者生存质量。

Recommendation categories